OpenAI acquired Orchestra Bio to expand into drug development and reported stronger model performance on legacy programming languages.
OpenAI tracker4 items
Separately, a report describes its pitch for advertising alongside AI-generated images in ChatGPT.
OpenAI acquires Orchestra Bio to expand into drug development
OpenAI has acquired drug development company Orchestra Bio, according to multiple reports. The acquisition is aimed at accelerating drug development workflows.
Why it matters: The deal expands OpenAI’s business into specialized drug development tools, beyond its general-purpose models and assistants.
OpenAI reports stronger GPT-6 performance on legacy programming languages
OpenAI says its latest models improve support for COBOL, Fortran and Visual Basic. GPT-6 Astra achieved an 87.4% test pass rate across 20 languages on MultiLangBench; GPT-6.1 Sol reached up to 97.9% accuracy on COBOL migration.
Why it matters: These results suggest greater potential for modernizing legacy business software, though benchmark performance does not establish reliability on production systems.
OpenAI reportedly pitches ads alongside AI-generated images in ChatGPT
Ad Age reports that OpenAI is pitching brands on advertising alongside AI-generated images in ChatGPT. The item does not establish a launch date or pricing.
Why it matters: The pitch signals a potential advertising revenue stream tied to ChatGPT’s image-generation experience.
OpenAI highlights Codex terminal voice and conversation branching
OpenAI’s developer update highlights talking to Codex in the terminal, tracking agents and forking conversations into separate worktrees. It also describes cloud environments where tasks continue after users close their laptops.
Why it matters: These capabilities support parallel development workflows and let developers continue cloud tasks without keeping a local session open.